Evaluation of CXCL12, carbohydrate antigen CA15.3, calcium and parathyroid hormone as potential biomarkers for bone metastasis in patients with breast cancer

Altimmime,Baqer A.; Rashid,Farah A.

doi:10.3892/wasj.2024.309

Evaluation of CXCL12, carbohydrate antigen CA15.3, calcium and parathyroid hormone as potential biomarkers for bone metastasis in patients with breast cancer

Authors:
- Baqer A. Altimmime
- Farah A. Rashid
View Affiliations

Affiliations: Department of Chemistry, College of Science, Al‑Nahrain University, Al-Jadiriya, Baghdad 10070, Iraq
Published online on: December 31, 2024 https://doi.org/10.3892/wasj.2024.309
Article Number: 21
Copyright : © Altimmime et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bone is a common site for tumor cells to settle in breast cancer. It has been reported that ~70% of patients with breast cancer experience bone metastasis. C‑X‑C motif chemokine ligand 12 (CXCL12) is a chemokine, which plays a crucial role in bone metastasis. Currently, the diagnostic biomarkers and risk factors associated with bone metastasis are limited. Therefore, the present study aimed to investigate whether CXCL12, carbohydrate antigen 15.3 (CA15.3), a comparative biomarker, and the bone‑related biomarkers, calcium (Ca²⁺) and parathyroid hormone (PTH), could be used as diagnostic biomarkers and independent risk factors for the early detection and treatment of bone metastasis in patients with breast cancer. The present case control and cross‑sectional study consisted of 25 participants who served as the control group, 25 patients newly diagnosed with breast cancer, 25 patients treated for primary breast cancer and 20 patients with breast cancer and bone metastasis. The CXCL12, CA15.3 and PTH levels were analyzed using sandwich ELISA. In addition, the Ca²⁺ levels were measured using colorimetric assay. The results revealed that the levels of CXCL12 were significantly increased. In addition, the levels of Ca²⁺ were slightly increased, whereas the PTH levels were notably decreased in patients with breast cancer experiencing bone metastasis. In addition, CXCL12 exhibited a higher diagnostic accuracy [area under the curve (AUC), 0.7940; P=0.0008] at a cut‑off value of >1,392 pg/ml compared with CA15.3 (AUC, 0.6579; P=0.0756; cut‑off, >21.50 U/ml). Additionally, PTH displayed a higher diagnostic accuracy (AUC, 0.7280; P=0.0092) for bone metastasis compared with Ca2+ (AUC, 0.6792; P=0.0427). Notably, the diagnostic accuracy was increased (AUC, 0.8040; P=0.0005) after combining CXCL12 and CA13.5. Furthermore, CXCL12, CA15.3 and PTH were identified as independent risk factors for bone metastasis. Overall, the results of the present study suggest that CXCL12, CA15.3 and PTH may be considered as promising independent risk factors, which could assist the early detection of bone metastasis and the selection of treatment for patients with breast cancer.

View Figures

View References

1	Zhang H, Zuh W, Biskup E, Yang W, Yang Z, Wang H, Qiu X, Zhang C and Hu G and Hu G: Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world data. J Bone Oncol. 11:38–50. 2018.PubMed/NCBI View Article : Google Scholar
2	Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 12:6243S–6249S. 2006.PubMed/NCBI View Article : Google Scholar
3	Gambardella C, Mongardini FM, Paolicelli M, Bentivoglio D, Cozzolino G, Ruggiero R, Pizza A, Tolone S, Del Genio G, Parisi S, et al: Role of inflammatory biomarkers (NLR, LMR, PLR) in the prognostication of malignancy in indeterminate thyroid nodules. Int J Mol Sci. 24(6466)2023.PubMed/NCBI View Article : Google Scholar
4	Tumer AA and Rashid FA: The relationship between circulating irisin and oxidative stress in gastric and colorectal cancer patients. Asian Pac J Cancer Prev. 23:2649–2654. 2022.PubMed/NCBI View Article : Google Scholar
5	Wang J, Loberg R and Taichman RS: The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev. 25:573–587. 2006.PubMed/NCBI View Article : Google Scholar
6	Sasaki K, Natsugoe S, Ishigami S, Matsumoto M, Okumura H, Setoyama T, Uchikado Y, Kita Y, Tamotsu K, Hanazono K, et al: Expression of CXCL12 and its receptor CXCR4 in esophageal squamous cell carcinoma. Oncol Rep. 21:65–71. 2009.PubMed/NCBI
7	Machelon V, Gaudin F, Camilleri-Broët S, Nasreddine S, Bouchet-Delbos L, Pujade-Lauraine E, Alexandre J, Gladieff L, Arenzana-Seisdedos F, Emilie D, et al: CXCL12 expression by healthy and malignant ovarian epithelial cells. BMC Cancer. 11(97)2011.PubMed/NCBI View Article : Google Scholar
8	Schrader AJ, Lechner O, Templin M, Dittmar KE, Machtens S, Mengel M, Probst-Kepper M, Franzke A, Wollensak T, Gatzlaff P, et al: CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer. 86:1250–1256. 2002.PubMed/NCBI View Article : Google Scholar
9	Potić Floranović M, Ristić Petrović A, Veličković F and Janković Veličković L: Expression and prognostic value of CXCL12/CXCR4/CXCR7 axis in clear cell renal cell carcinoma. Clin Exp Nephrol. 25:1057–1069. 2021.PubMed/NCBI View Article : Google Scholar
10	Mousavi A, Hashemzadeh S, Bahrami T, Estiar MA, Feizi MAH, Pouladi N, Rostamizadeh L and Sakhinia E: Expression patterns of CXCL12 and its receptor in colorectal carcinoma. Clin Lab. 64:871–876. 2018.PubMed/NCBI View Article : Google Scholar
11	Sun Y, Mao X, Fan C, Liu C, Guo A, Guan S, Jin Q, Li B, Yao F and Jin F: CXCL12-CXCR4 axis promotes the natural selection of breast cancer cell metastasis. Tumour Biol. 35:7765–7773. 2014.PubMed/NCBI View Article : Google Scholar
12	Teicher BA and Fricker SP: CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 16:2927–2931. 2010.PubMed/NCBI View Article : Google Scholar
13	Łukaszewicz-Zając M, Mroczko B, Kozłowski M and Szmitkowski M: The serum concentrations of chemokine CXCL12 and its specific receptor CXCR4 in patients with esophageal cancer. Dis Markers. 2016(7963895)2016.PubMed/NCBI View Article : Google Scholar
14	Dabrowska E, Przylipiak A, Zajkowska M, Piskor BM, Sidorkiewicz I, Szmitkowski M and Lawicki S: Possible diagnostic application of CXCL12 and CXCR4 as tumor markers in breast cancer patients. Anticancer Res. 40:3221–3229. 2020.PubMed/NCBI View Article : Google Scholar
15	Fejzić H, Mujagić S, Azabagić S and Burina M: Tumor marker CA 15-3 in breast cancer patients. Acta Med Acad. 44:39–46. 2015.PubMed/NCBI View Article : Google Scholar
16	Zhang Y, Zhao J, Wang Y, Cai W, Zhang X, Li K, Liu W, Zhao Y and Kang H: Changes of tumor markers in patients with breast cancer during postoperative adjuvant chemotherapy. Dis Markers. 2022(7739777)2022.PubMed/NCBI View Article : Google Scholar
17	Chu WG and Ryu DW: Clinical significance of serum CA15-3 as a prognostic parameter during follow-up periods in patients with breast cancer. Ann Surg Treat Res. 90:57–63. 2016.PubMed/NCBI View Article : Google Scholar
18	Yerushalmi R, Tyldesley S, Kennecke H, Speers C, Woods R, Knight B and Gelmon KA: Tumor markers in metastatic breast cancer subtypes: Frequency of elevation and correlation with outcome. Ann Oncol. 23:338–345. 2012.PubMed/NCBI View Article : Google Scholar
19	Sturgeon CM, Lai CL and Duffy MJ: Serum tumour markers: How to order and interpret them. BMJ. 339(b3527)2009.PubMed/NCBI View Article : Google Scholar
20	Prevarskaya N, Ouadid-Ahidouch H, Skryma R and Shuba Y: Remodelling of Ca2+ transport in cancer: How it contributes to cancer hallmarks? Philos Trans R Soc Lond B Biol Sci. 369(20130097)2014.PubMed/NCBI View Article : Google Scholar
21	Monteith GR, Davis FM and Roberts-Thomson SJ: Calcium channels and pumps in cancer: Changes and consequences. J Biol Chem. 287:31666–31673. 2012.PubMed/NCBI View Article : Google Scholar
22	Monteith GR, McAndrew D, Faddy HM and Roberts-Thomson SJ: Calcium and cancer: Targeting Ca2+ transport. Nat Rev Cancer. 7:519–530. 2007.PubMed/NCBI View Article : Google Scholar
23	Schwartz GG: Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases. Cancer Epidemiol Biomarkers Prev. 17:478–483. 2008.PubMed/NCBI View Article : Google Scholar
24	Yang Z, Yue Z, Ma X and Xu Z: Calcium homeostasis: A potential vicious cycle of bone metastasis in breast cancers. Front Oncol. 10(293)2020.PubMed/NCBI View Article : Google Scholar
25	Almuradova E and Cicin I: Cancer-related hypercalcemia and potential treatments. Front Endocrinol. 14(1039490)2023.PubMed/NCBI View Article : Google Scholar
26	Huang P, Lan M, Peng AF, Yu QF, Chen WZ, Liu ZL, Liu JM and Huang SH: Serum calcium, alkaline phosphotase and hemoglobin as risk factors for bone metastases in bladder cancer. PLoS One. 12(e0183835)2017.PubMed/NCBI View Article : Google Scholar
27	Potts JT and Gardella TJ: Chapter 6-Parathyroid Hormone and Calcium Homeostasis, in Pediatric Bone. (Second Edition), Glorieux FH, Pettifor JM, and Jüppner H: Academic Press, San Diego. pp109-140, 2012.
28	Brown HK, Allocca G, Ottewell PD, Wang N, Brown NJ, Croucher PI, Eaton CL and Holen I: Parathyroid hormone (PTH) increases skeletal tumour growth and alters tumour distribution in an in vivo model of breast cancer. Int J Mol Sci. 19(2920)2018.PubMed/NCBI View Article : Google Scholar
29	Zissimopoulos A, Stellos K, Matthaios D, Petrakis G, Parmenopoulou V, Babatsikou F, Matthaiou E, Theodosiadou E, Hountis P and Koutis C: Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy. J BUON. 14:463–472. 2009.PubMed/NCBI
30	Tähtelä R and Thölix E: Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as biomarkers of metastatic bone disease in breast cancer. Anticancer Res. 16:2289–2293. 1996.PubMed/NCBI
31	Wang W, Xu X, Tian B, Wang Y, Du L, Sun T, Shi Y, Zhao X and Jing J: The diagnostic value of serum tumor biomarkers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer. Clin Chim Acta. 470:51–55. 2017.PubMed/NCBI View Article : Google Scholar
32	Manders K, van de Poll-Franse LV, Creemers GJ, Vreugdenhil G, van der Sangen MJ, Nieuwenhuijzen GA, Roumen RM and Voogd AC: Clinical management of women with metastatic breast cancer: A descriptive study according to age group. BMC Cancer. 6(179)2006.PubMed/NCBI View Article : Google Scholar
33	Coleman RE, Smith P and Rubens RD: Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer. 77:336–340. 1998.PubMed/NCBI View Article : Google Scholar
34	Motyka J, Gacuta E, Kicman A, Kulesza M, Malinowski P and Ławicki S: CXCL12 and CXCR4 as potential early biomarkers for luminal A and luminal B subtypes of breast cancer. Cancer Manag Res. 15:573–589. 2023.PubMed/NCBI View Article : Google Scholar
35	Neesanun S and Sriuranpong V: Association of plasma CXCL12 level and bone metastasis in advance stage non-small cell lung cancer patients in King Chulalongkorn Memorial Hospital. J Clin Oncol. 33 (15_suppl)(e19099)2015.
36	Turanli S and Cetin A: Prognostic role of serum cancer antigen 15-3 in breast cancer patients with isolated bone metastases. Biomarkers. 15:418–423. 2010.PubMed/NCBI View Article : Google Scholar
37	Cao R and Wang LP: Serological diagnosis of liver metastasis in patients with breast cancer. Cancer Biol Med. 9:57–62. 2012.PubMed/NCBI View Article : Google Scholar
38	Chen WZ, Shen JF, Zhou Y, Chen XY, Liu JM and Liu ZL: Clinical characteristics and risk factors for developing bone metastases in patients with breast cancer. Sci Rep. 7(11325)2017.PubMed/NCBI View Article : Google Scholar